The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: It is unknown whether different β-blockers (BBs) have variable effects on long-term survival of patients with heart failure with reduced ejection fraction (HFrEF). This study compares the effects of two BBs, carvedilol and bisoprolol, on survival in patients with HFrEF. Methods: The Korean Acute Heart Failure (KorAHF) registry is a prospective multicenter cohort that includes 5,625 patients who were hospitalized for acute heart failure (AHF). We selected 3,016 patients with HFrEF and divided this study population into two groups: BB at discharge (n = 1,707) or no BB at discharge (n = 1,309). Among patients with BB at discharge, subgroups were formed based on carvedilol prescription (n = 831), or bisoprolol prescription (n = 553). Propensity score matching analysis was performed. Results: Among patients who were prescribed a BB at discharge, 60.5% received carvedilol and 32.7% received bisoprolol. There was a significant reduction in allcause mortality in those patients with HFrEF prescribed a BB at discharge compared to those who were not (BB vs. no BB, 26.1% vs. 40.8%; hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.52 to 0.67; p < 0.001). However, there was no significant difference in the rate of all-cause mortality between those receiving different types of BB (carvedilol vs. bisoprolol, 27.5% vs. 23.5%; HR, 1.21; 95% CI, 0.99 to 1.47; p = 0.07). Similar results were observed after propensity score matching analysis (508 pairs, 26.2% vs. 23.8%; HR, 1.10; 95% CI, 0.86 to 1.40; p = 0.47). Conclusions: In the treatment of AHF with reduced EF after hospitalization, mortality benefits of carvedilol and bisoprolol were comparable.
Abstract
Background/Aims: It is unknown whether different β-blockers (BBs) have variable effects on long-term survival of patients with heart failure with reduced ejection fraction (HFrEF). This study compares the effects of two BBs, carvedilol and bisoprolol, on survival in patients with HFrEF. Methods: The Korean Acute Heart Failure (KorAHF) registry is a prospective multicenter cohort that includes 5,625 patients who were hospitalized for acute heart failure (AHF). We selected 3,016 patients with HFrEF and divided this study population into two groups: BB at discharge (n = 1,707) or no BB at discharge (n = 1,309). Among patients with BB at discharge, subgroups were formed based on carvedilol prescription (n = 831), or bisoprolol prescription (n = 553). Propensity score matching analysis was performed. Results: Among patients who were prescribed a BB at discharge, 60.5% received carvedilol and 32.7% received bisoprolol. There was a significant reduction in allcause mortality in those patients with HFrEF prescribed a BB at discharge compared to those who were not (BB vs. no BB, 26.1% vs. 40.8%; hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.52 to 0.67; p < 0.001). However, there was no significant difference in the rate of all-cause mortality between those receiving different types of BB (carvedilol vs. bisoprolol, 27.5% vs. 23.5%; HR, 1.21; 95% CI, 0.99 to 1.47; p = 0.07). Similar results were observed after propensity score matching analysis (508 pairs, 26.2% vs. 23.8%; HR, 1.10; 95% CI, 0.86 to 1.40; p = 0.47). Conclusions: In the treatment of AHF with reduced EF after hospitalization, mortality benefits of carvedilol and bisoprolol were comparable.
참고문헌 (27)
- Ponikowski P, "2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC", Eur Heart J, 37, pp.2129~2200 (2016)
- Yancy CW, "2013 ACCF", AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation, J Am Coll Cardiol, pp.2013, 62[DOI]
- MERIT-HF Study Group, "Effect of metoprolol CR", XL in chronic heart failure : Metoprolol CR, Lancet, pp.1999, 353[DOI]
- CIBIS-II Investigators and Committees, "The Cardiac Insufficiency Bisoprolol Study II(CIBIS-II) : a randomised trial", Lancet, 353, pp.9~13 (1999)
- Packer M, "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group", N Engl J Med, 334, pp.1349~1355 (1996)
- Packer M, "Effect of carvedilol on the morbidity of patients with severe chronic heart failure : results of the carvedilol prospective randomized cumulative survival(COPERNICUS)study", Circulation, 106, pp.2194~2199 (2002)
- Gilbert EM, "Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart", Circulation, 94, pp.2817~2825 (1996)
- Poole-Wilson PA, "Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial(COMET) : randomised controlled trial", Lancet, 362, pp.7~13 (2003)
- Pasternak B, "Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure", JAMA Intern Med, 174, pp.1597~1604 (2014)
- Frohlich H, "Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure", Clin Res Cardiol, 106, pp.711~721 (2017)
- Frohlich H, "Carvedilol compared with metoprolol succinate in the treatment and prognosis of patients with stable chronic heart failure : carvedilol or metoprolol evaluation study", Circ Heart Fail, 8, pp.887~896 (2015)
- Packer M, "Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure : results of a meta-analysis", Am Heart J, 141, pp.899~907 (2001)
- Chatterjee S, "Benefits of β blockers in patients with heart failure and reduced ejection fraction : network meta-analysis", BMJ, 346, pp.f55~ (2013)
- 이상언, "Clinical Characteristics and Outcome of Acute Heart Failure in Korea: Results from the Korean Acute Heart Failure Registry (KorAHF)", Korean Circulation Journal, 47(3), pp.341~353 (2017), 대한심장학회
- Lee SE, "A multicentre cohort study of acute heart failure syndromes in Korea : rationale, design, and interim observations of the Korean Acute Heart Failure(KorAHF)registry", Eur J Heart Fail, 16, pp.700~708 (2014)
- Schiller NB, "American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms", J Am Soc Echocardiogr, 2, pp.358~367 (1989)
- Levey AS, "Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate", Ann Intern Med, 145, pp.247~254 (2006)
- Hori M, "Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure : the Multicenter Carvedilol Heart Failure Dose Assessment(MUCHA)trial", Am Heart J, 147, pp.324~330 (2004)
- Di Lenarda A, "Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group", J Am Coll Cardiol, 33, pp.1926~1934 (1999)
- Fonarow GC, "Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival : an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure(OPTIMIZE-HF)", Am Heart J, 153, pp.82~ (2007)
- Hori M, "Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure : results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II(MAIN-CHF II)study", Heart Vessels, 29, pp.238~247 (2014)
- Bolling R, "Comparison of the clinical outcome of different beta-blockers in heart failure patients : a retrospective nationwide cohort study", Eur J Heart Fail, 16, pp.678~684 (2014)
- Konishi M, "Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure", Circ J, 74, pp.1127~1134 (2010)
- Butler J, "Beta-blocker use and outcomes among hospitalized heart failure patients", J Am Coll Cardiol, 47, pp.2462~2469 (2006)
- Metra M, "Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET", Eur J Heart Fail, 9, pp.901~909 (2007)
- Fonarow GC, "Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure : findings from the OPTIMIZE-HF program", J Am Coll Cardiol, 52, pp.190~199 (2008)
- Gattis WA, "Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF)trial", J Am Coll Cardiol, 43, pp.1534~1541 (2004)